<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Samsung Biologics Co Ltd — News on 6ix</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd</link>
<description>Latest news and press releases for Samsung Biologics Co Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 06:50:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/samsung-biologics-co-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68362e3578dffbe2df146bf7.webp</url>
<title>Samsung Biologics Co Ltd</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd</link>
</image>
<item>
<title>Samsung Biologics Reports First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-reports-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-reports-first-quarter-2026-financial-results</guid>
<pubDate>Wed, 22 Apr 2026 06:50:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), reported financial results for the first quarter of fiscal year 2026.</description>
</item>
<item>
<title>Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-leads-climate-transparency-with-independent-validation-of-product-carbon-footprint-system</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-leads-climate-transparency-with-independent-validation-of-product-carbon-footprint-system</guid>
<pubDate>Fri, 06 Feb 2026 13:00:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced that its product carbon footprint (PCF) system has been validated by Det Norske Veritas (DNV), an independent third-party assurance provider, confirming alignment with globally recognized standards.</description>
</item>
<item>
<title>CEPI and Samsung Biologics collaborate to strengthen outbreak-ready vaccine production and global access</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/cepi-and-samsung-biologics-collaborate-to-strengthen-outbreak-ready-vaccine-production-and-global-access</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/cepi-and-samsung-biologics-collaborate-to-strengthen-outbreak-ready-vaccine-production-and-global-access</guid>
<pubDate>Tue, 03 Feb 2026 13:00:00 GMT</pubDate>
<description>The Coalition for Epidemic Preparedness Innovations (CEPI) and Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced a partnership to strengthen vaccine manufacturing preparedness for future epidemic and pandemic threats. The collaboration will see Samsung Biologics join CEPI's Vaccine Manufacturing Facility Network (VMFN) with the aim of accelerating the availability of protein-based vaccines and advancing equitable access to t</description>
</item>
<item>
<title>Samsung Biologics receives EcoVadis Platinum, the highest sustainability rating</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-receives-ecovadis-platinum-the-highest-sustainability-rating</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-receives-ecovadis-platinum-the-highest-sustainability-rating</guid>
<pubDate>Wed, 28 Jan 2026 12:00:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced that it has received the EcoVadis' Platinum Sustainability Rating, the highest level of recognition for corporate sustainability performance.</description>
</item>
<item>
<title>Samsung Biologics reports fourth quarter and fiscal year 2025 financial results</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-reports-fourth-quarter-and-fiscal-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-reports-fourth-quarter-and-fiscal-year-2025-financial-results</guid>
<pubDate>Wed, 21 Jan 2026 07:20:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), reported financial results for the fourth quarter and fiscal year 2025.</description>
</item>
<item>
<title>Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-expands-u-manufacturing-224300355</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-expands-u-manufacturing-224300355</guid>
<pubDate>Sun, 21 Dec 2025 22:43:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced that its wholly owned U.S. subsidiary, Samsung Biologics America, has entered into a definitive agreement to acquire 100% of Human Genome Sciences from GSK (LSE/NYSE: GSK). This strategic move secures Samsung Biologics' first U.S.-based manufacturing site, a significant expansion of the company's global footprint and its long-term commitment to the U.S. market.</description>
</item>
<item>
<title>Samsung Biologics recognized as a global leader in water security</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-recognized-global-leader-233000880</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-recognized-global-leader-233000880</guid>
<pubDate>Wed, 10 Dec 2025 23:30:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced that it has received from the Carbon Disclosure Project (CDP) an 'A' rating in Water Security.</description>
</item>
<item>
<title>Samsung Biologics completes spin-off to strengthen its focus as a pure-play CDMO</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-completes-spin-off-120000432</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-completes-spin-off-120000432</guid>
<pubDate>Mon, 03 Nov 2025 12:00:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS) today announced the completion of its spin-off of Samsung Bioepis, reinforcing its strategic focus and business specialization as a leading pure-play Contract Development and Manufacturing Organization (CDMO).</description>
</item>
<item>
<title>Samsung Biologics reports third quarter 2025 financial results</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-reports-third-quarter-065000449</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-reports-third-quarter-065000449</guid>
<pubDate>Tue, 28 Oct 2025 06:50:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced its financial results for the third quarter of fiscal year 2025.</description>
</item>
<item>
<title>Samsung Biologics Introduces Optimized Manufacturing Framework, ExellenS™</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-introduces-optimized-manufacturing-110000602</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-introduces-optimized-manufacturing-110000602</guid>
<pubDate>Thu, 09 Oct 2025 11:00:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today unveiled ExellenS TM – an optimized manufacturing framework applied across the company's biomanufacturing network.</description>
</item>
<item>
<title>Samsung Biologics reports second quarter 2025 financial results</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-reports-second-quarter-065400542</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-reports-second-quarter-065400542</guid>
<pubDate>Wed, 23 Jul 2025 06:54:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced its financial results for the second quarter of fiscal year 2025.</description>
</item>
<item>
<title>Samsung Biologics launches drug screening services, Samsung Organoids</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-launches-drug-screening-233000485</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-launches-drug-screening-233000485</guid>
<pubDate>Sun, 15 Jun 2025 23:30:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced the launch of Samsung Organoids – advanced drug screening services to support clients in drug discovery and development.</description>
</item>
<item>
<title>Samsung Biologics reports first quarter 2025 financial results</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-reports-first-quarter-064600359</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-reports-first-quarter-064600359</guid>
<pubDate>Wed, 23 Apr 2025 06:46:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced financial results for the first quarter of fiscal year 2025.</description>
</item>
<item>
<title>Samsung Biologics recognized for leadership band in water security</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-recognized-leadership-band-120000528</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-recognized-leadership-band-120000528</guid>
<pubDate>Wed, 12 Feb 2025 12:00:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a global contract manufacturing and development organization (CDMO), today announced that it has received 'Leadership' status and an A- rating for water security from the Carbon Disclosures Project (CDP), underscoring the company's efficient water resources management. The company participated in the category for the first time.</description>
</item>
<item>
<title>Samsung Biologics reports fourth quarter and fiscal year 2024 financial results</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-reports-fourth-quarter-070600497</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-reports-fourth-quarter-070600497</guid>
<pubDate>Wed, 22 Jan 2025 07:06:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced financial results for the fourth quarter and fiscal year 2024.</description>
</item>
<item>
<title>Samsung Biologics presents business updates at 2025 J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-presents-business-updates-014000868</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-presents-business-updates-014000868</guid>
<pubDate>Wed, 15 Jan 2025 01:40:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced its latest business achievements and 2025 outlook at the 43rd J.P. Morgan Healthcare Conference, which was held in San Francisco between January 13-16.</description>
</item>
</channel>
</rss>